New Drugs Shine But Biosimilars Blunt Roche Revenue Rise
MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.
MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.